Table 2.
Expression of CD25, CD18, CD54, CD2, CD49d surface markers on PBMC from healthy donors (HD, n=3) and cancer patients (Ca, n=2) stimulated with proTα and its peptide fragments
| Stimulation conditions | CD25+ | CD54+ | CD18+ | CD56+/CD49d+a | CD56+/CD2+a | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| HD | Ca | HD | Ca | HD | Ca | HD | Ca | HD | Ca | |
| - | 10.3±2.1 | 7.2±2.2 | 35.7±1.8 | 24.6±4.2 | 49.7±7.0 | 29.2±3.8 | 41.9±3.4 | 22.8±6.3 | 28.6±2.4 | 17.9±5.8 |
| proTα | 23.1±3.0* | 13.2±1.9* | 48.4±1.3 | 31.2±7.1 | 75.0±10.2 | 48.4±5.4* | 48.1±5.1 | 36.1±4.8 | 34.2±8.9 | 25.8±1.9 |
| proTα(103-109) | 19.5±2.5* | 13.3±2.6* | 44.2±2.9 | 38.5±6.9 | 78.1±2.9* | 44.2±1.3* | 49.1±2.9 | 34.7±1.4 | 35.6±8.5 | 28.4±4.6 |
| proTα(89-102) | 18.0±2.2* | 12.3±2.0* | 43.1±3.7 | 36.3±3.3 | 68.5±5.0 | 31.5±7.5 | 49.4±2.6 | 33.5±3.4 | 28.0±4.7 | 28.4±5.7 |
| proTα(31-87) | 11.2±1.1 | 9.7±1.1 | 38.4±7.1 | 25.6±4.2 | 42.4±0.9 | 19.8±2.2 | 40.8±4.3 | 16.3±2.5 | 21.3±4.8 | 23.1±2.1 |
| proTα(21-30) | 9.0±1.3 | 8.8±0.6 | 35.8±4.7 | 26.0±4.9 | 43.9±3.0 | 26.3±5.5 | 41.8±3.9 | 23.2±5.7 | 20.7±3.2 | 18.9±1.5 |
| proTα(1-14) | 13.2±1.6 | 10.4±1.8 | 39.7±2.8 | 31.9±6.7 | 48.7±1.8 | 29.9±2.8 | 42.3±6.0 | 24.7±4.6 | 25.1±6.9 | 24.2±2.4 |
Data are expressed as the mean % of positive cells on gated lymphocytes ± SD from the pooled data
aPercentage of positive cells coexpressing both surface markers
*P<0.05 versus % positive cells of nonstimulated (−) cultures